Cover Image
市場調查報告書

類風濕性關節炎:開發中產品分析

Rheumatoid Arthritis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232779
出版日期 內容資訊 英文 1186 Pages
訂單完成後即時交付
價格
Back to Top
類風濕性關節炎:開發中產品分析 Rheumatoid Arthritis - Pipeline Review, H2 2016
出版日期: 2016年12月28日 內容資訊: 英文 1186 Pages
簡介

類風濕性關節炎是慢性的自體免疫疾病,最終導致成為畸形原因的骨骼破壞。身體的免疫系統無法識別自己與異物,而以異常的形式工作。關節首先受到影響,發展為發硬、發炎。還有這個疾病也影響其他器官。 類風濕性關節炎由於遺傳或其他特殊的環境要素引起。女性特別容易得,拖延治療會引起包含障礙的各種併發症。

本報告提供類風濕性關節炎的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

類風濕性關節炎概要

治療藥的開發

類風濕性關節炎:企業開發中的治療藥

類風濕性關節炎:大學/機關研究中的治療藥

類風濕性關節炎:開發中產品概況

類風濕性關節炎:企業開發中的產品

類風濕性關節炎:大學/機關研究中的產品

類風濕性關節炎的治療藥開發作的企業

類風濕性關節炎:治療藥的評估

藥物簡介

類風濕性關節炎:暫停中的計劃

類風濕性關節炎:開發中止的產品

類風濕性關節炎:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8865IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis - Pipeline Review, H2 2016, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 28, 44, 59, 12, 223, 50 and 9 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 12 molecules, respectively.

Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Rheumatoid Arthritis Overview
  • Therapeutics Development
  • Rheumatoid Arthritis - Therapeutics under Development by Companies
  • Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes
  • Rheumatoid Arthritis - Pipeline Products Glance
  • Rheumatoid Arthritis - Products under Development by Companies
  • Rheumatoid Arthritis - Products under Investigation by Universities/Institutes
  • Rheumatoid Arthritis - Companies Involved in Therapeutics Development
  • Rheumatoid Arthritis - Therapeutics Assessment
  • Drug Profiles
  • Rheumatoid Arthritis - Dormant Projects
  • Rheumatoid Arthritis - Discontinued Products
  • Rheumatoid Arthritis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Rheumatoid Arthritis, H2 2016
  • Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Development by Companies, H2 2016 (Contd..16)
  • Number of Products under Development by Companies, H2 2016 (Contd..17)
  • Number of Products under Development by Companies, H2 2016 (Contd..18)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Development by Companies, H2 2016 (Contd..24)
  • Products under Development by Companies, H2 2016 (Contd..25)
  • Products under Development by Companies, H2 2016 (Contd..26)
  • Products under Development by Companies, H2 2016 (Contd..27)
  • Products under Development by Companies, H2 2016 (Contd..28)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Rheumatoid Arthritis - Pipeline by 3SBio Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by 4D Pharma Plc, H2 2016
  • Rheumatoid Arthritis - Pipeline by A&G Pharmaceutical Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by AB Science SA, H2 2016
  • Rheumatoid Arthritis - Pipeline by AB2 Bio Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by AbbVie Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Ablynx NV, H2 2016
  • Rheumatoid Arthritis - Pipeline by ACEA Biosciences Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Adello Biologics LLC, H2 2016
  • Rheumatoid Arthritis - Pipeline by Advinus Therapeutics Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by AlphaMab Co Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Alteogen Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Amgen Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Amura Holdings Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Anacor Pharmaceuticals Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by AnGes MG Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Applied Genetic Technologies Corp, H2 2016
  • Rheumatoid Arthritis - Pipeline by Aptevo Therapeutics Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by ARA Healthcare Pvt Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Arena Pharmaceuticals Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by arGEN-X BV, H2 2016
  • Rheumatoid Arthritis - Pipeline by Arrien Pharmaceuticals LLC, H2 2016
  • Rheumatoid Arthritis - Pipeline by Arthrogen BV, H2 2016
  • Rheumatoid Arthritis - Pipeline by Asahi Kasei Pharma Corp, H2 2016
  • Rheumatoid Arthritis - Pipeline by Asana BioSciences LLC, H2 2016
  • Rheumatoid Arthritis - Pipeline by Astellas Pharma Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by AstraZeneca Plc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Atlantic Bio Sci LLC, H2 2016
  • Rheumatoid Arthritis - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Avexxin AS, H2 2016
  • Rheumatoid Arthritis - Pipeline by Axxam SpA, H2 2016
  • Rheumatoid Arthritis - Pipeline by BCN Peptides SA, H2 2016
  • Rheumatoid Arthritis - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Biocad, H2 2016
  • Rheumatoid Arthritis - Pipeline by Biocon Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Biokine Therapeutics Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by BioLingus AG, H2 2016
  • Rheumatoid Arthritis - Pipeline by BioLite Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Bionovis SA, H2 2016
  • Rheumatoid Arthritis - Pipeline by BioTherapeutics Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Biozeus, H2 2016
  • Rheumatoid Arthritis - Pipeline by Bird Rock Bio Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Rheumatoid Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Rheumatoid Arthritis - Pipeline by Can-Fite BioPharma Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Cardax Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by CASI Pharmaceuticals Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by CEL-SCI Corp, H2 2016
  • Rheumatoid Arthritis - Pipeline by Celgene Corp, H2 2016
  • Rheumatoid Arthritis - Pipeline by Cellceutix Corp, H2 2016
  • Rheumatoid Arthritis - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Celltrion Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by ChemoCentryx Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by ChironWells GmbH, H2 2016
  • Rheumatoid Arthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016
  • Rheumatoid Arthritis - Pipeline by CJ HealthCare Corp, H2 2016
  • Rheumatoid Arthritis - Pipeline by Clevexel Pharma SA, H2 2016
  • Rheumatoid Arthritis - Pipeline by CLL Pharma SA, H2 2016
  • Rheumatoid Arthritis - Pipeline by Coherus BioSciences Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Commence Bio Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Compugen Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Confluence Life Sciences Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by CSL Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Diamyd Medical AB, H2 2016
  • Rheumatoid Arthritis - Pipeline by Domainex Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Eisai Co Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Eli Lilly and Company, H2 2016
  • Rheumatoid Arthritis - Pipeline by Enceladus Pharmaceuticals BV, H2 2016
  • Rheumatoid Arthritis - Pipeline by Endocyte Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Enzene Biosciences Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Fountain Biopharma Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Galapagos NV, H2 2016
  • Rheumatoid Arthritis - Pipeline by Gene Techno Science Co Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Genentech Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Genosco Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Gilead Sciences Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Griffin Discoveries BV, H2 2016
  • Rheumatoid Arthritis - Pipeline by Han Wha Pharma Co Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Handok Inc, H2 2016
  • Rheumatoid Arthritis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Hansa Medical AB, H2 2016
  • Rheumatoid Arthritis - Pipeline by Hanwha Chemical Corp, H2 2016
  • Rheumatoid Arthritis - Pipeline by HEC Pharm Co Ltd, H2 2016
  • Rheumatoid Arthritis - Pipeline by Hetero Drugs Ltd, H2 2016

List of Figures

  • Number of Products under Development for Rheumatoid Arthritis, H2 2016
  • Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top